Neogen Corporation (NEOG) has recently entered into a strategic licensing and supply agreement with Syngenta. Under the agreement, Neogen will have exclusive rights to market and sell Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada. The agreement is likely to expand Neogen’s rodenticide portfolio with well-established and highly effective products. NEOG’s Likely Stock Trend Following the NewsFollowing the announcement, shares of NEOG moved 4.7% north to $6.70 in yesterday’s aft ...

Bíldudalur, 20 May 2025 Icelandic Salmon is the parent company of Arnarlax and its subsidiaries, which are involved in salmon farming and processing in Iceland. The companies are collectively referred to as "Icelandic Salmon" or the "Group". In the first quarter, Icelandic Salmon experienced biological challenges at sea. To protect animal welfare, some volumes were harvested early at low average weights. Results were marked by mortality-related costs, low harvest volumes, and a weaker market due to increase ...

Company Overview - SalMar ASA is one of the world's largest and most efficient producers of salmon, with farming operations in Central Norway, Northern Norway, Offshore, and Iceland, as well as significant harvesting and secondary processing operations [9] - The company owns 50% of Scottish Sea Farms Ltd, further enhancing its market presence [9] Recent Developments - SalMar has completed the purchase of a controlling stake in AS Knutshaugfisk, which has 3,466 tons MTB in licenses and four farming locations in Central Norway [2] - A merger plan between Wilsgård AS and SalMar Farming AS has been approved, with SalMar holding a 37.5% stake in Wilsgård. This merger is expected to enhance operational efficiency and financial robustness [3][4] Financial Performance - In Q1 2025, SalMar reported an operational EBIT of NOK 798 million with a harvest volume of 42,700 tonnes, resulting in an operational EBIT per kg of NOK 18.7 [7] - The harvest volume for Norway was 40,400 tonnes, with an operational EBIT of NOK 852 million, translating to NOK 21.1 per kg [7] - The first quarter was characterized by low harvest volumes, primarily due to late harvesting and fish welfare considerations, leading to a high share of downgraded fish and negatively impacting price achievement [7] Future Outlook - For 2025, SalMar expects a total harvest volume of 294,000 tonnes, representing a 17% growth compared to 2024, with specific contributions from Norway, SalMar Ocean, Iceland, and Scottish Sea Farms [5] - The company anticipates strong demand for its products despite global market uncertainties and expects lower global supply growth in the latter half of 2025 [6]

Core Insights - Mowi reported operating revenues of EUR 1.36 billion and an operational profit of EUR 214 million in Q1 2025, showing an increase compared to the same quarter last year due to strong biological and operational performance [1][2] - The company harvested 108,000 tonnes in Q1 2025, a 12% increase year-on-year, and maintains a harvest volume guidance of 530,000 tonnes for the year, projecting a 6% annual growth [3][5] - Mowi's feed segment also performed well, contributing to the overall growth in harvest volumes, with record-high earnings and sold volumes for the first quarter [7][8] Financial Performance - Mowi's operational profit of EUR 214 million reflects strong performance driven by high harvest volumes and improved cost management [1] - The company plans to pay a quarterly dividend of NOK 1.70 per share, indicating confidence in its financial health [8] Market Dynamics - Global supply growth in Q1 2025 was 13% in Europe and 8% globally, attributed to a one-off correction after three years of challenging biological conditions [6][7] - Demand for salmon remained strong across Europe, the Americas, and Asia, although high supply growth has put pressure on market prices [6] Strategic Initiatives - Mowi's strategic focus on volume growth across the value chain is evident, with a projected increase in harvest volumes from 375,000 tonnes in 2018 to 600,000 tonnes by the end of 2026, representing a CAGR of 5.1% [5] - The company has increased its ownership of Nova Sea from 49% to 95%, which is expected to further enhance its harvest capacity [3]

Harvested volume for Q1 2025 was 6.383 tonnes gutted weight (GWT). The complete report for Q1 2025 will be published May 21th 2025.For further information, please contact:Róbert Róbertsson, CFO of Kaldvik AS: +354 843 0086 (mobile)robert.robertsson@kaldvik.isAbout Kaldvik ASKaldvik AS is one of the leading salmon farmers in Iceland. Kaldvik AS has a well-developed and fully integrated value-chain controlling all steps from hatchery to sales, enabling the group to provide its customers with a sustainable pre ...

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were approximately $585 million, representing a 4.2% decline compared to $611 million in Q1 2024. On a currency neutral basis, this reflects a 1.5% year-over-year decrease, primarily driven by lower sales in the Life Science Group [11][12] - GAAP gross margin for Q1 2025 was 52.3%, down from 53.4% in Q1 2024, attributed to increased restructuring costs [13] - Non-GAAP gross margin for Q1 2025 was 53.8%, lower than 54.2% in Q1 2024, while non-GAAP operating margin improved to 10.8% from 9.7% year-over-year [15][16] - GAAP net income for Q1 2025 was $71 million, or $2.54 diluted earnings per share [17] Business Line Data and Key Metrics Changes - Life Science Group sales in Q1 2025 were $229 million, down 5.4% on a reported basis and 3.5% on a currency neutral basis, reflecting ongoing softness in the biotech and academic research market [12] - Clinical Diagnostics Group sales were approximately $357 million, a decrease of 3.2% on a reported basis, but effectively flat on a currency neutral basis [13] - Process Chromatography business experienced mid-teens growth year-over-year, with expectations of high single-digit growth for 2025 [12][19] Market Data and Key Metrics Changes - In the Americas and Asia Pacific, currency neutral sales decreased, partially offset by increased sales in EMEA [12] - Demand for consumables remained strong, while instrument sales faced challenges, particularly in the academic and biotech sectors [41][71] Company Strategy and Development Direction - The company is focused on driving consistent top-line growth and operational efficiency to achieve substantial margin expansion over the coming years [27] - The acquisition of Stila Technology is on track for closing by the end of Q3 2025, which will enhance the company's digital PCR offerings [8][10] - The company is implementing mitigation strategies for tariff impacts, including surcharges and regionalizing supply chains [7][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging macro environment with academic market headwinds due to government funding and global trade disruptions [5] - The company expects total currency neutral revenue to decline by approximately 1% to 1.5% for 2025, reflecting softer academic research funding and reduced demand from biotech customers [20][21] - Management remains optimistic about the long-term growth potential in life sciences and diagnostics despite current challenges [28][29] Other Important Information - The company generated $130 million in net cash from operating activities in Q1 2025, compared to $70 million in Q1 2024 [18] - Free cash flow for Q1 2025 was $96 million, significantly higher than $30 million in Q1 2024, with a full-year target of approximately $310 million to $330 million for 2025 [18][19] Q&A Session Summary Question: Impact of tariffs on guidance - Management discussed the gross impact of tariffs and mitigation efforts, including potential surcharges and pre-positioning inventory [33][36] Question: Academic funding expectations - Management noted a 28% reduction in overall funding and challenges in instrument sales, while consumables remained strong [39][40] Question: Growth gap between consumables and equipment - Instrument sales saw a sequential decline of about 10%, while consumables held up well [46] Question: Tariff exposure specifics - Management clarified that the majority of revenue in China comes from U.S. products, with ongoing evaluations of tariff impacts [47][49] Question: Free cash flow maintenance despite lower operating margin - Management emphasized focus on working capital management and inventory control to sustain free cash flow [96]

Bio-Rad Laboratories (BIO) Q1 2025 Earnings Call May 01, 2025 05:30 PM ET Company Participants Edward Chung - VP, IRJonathan DiVincenzo - President & Chief Operating OfficerRoop Lakkaraju - Executive VP & CFONorman Schwartz - Chairman & CEOBrandon Couillard - Managing Director Conference Call Participants Patrick Donnelly - Managing Director, Equity Research AnalystDan Leonard - Managing Director & Research AnalystMatthew Stanton - AnalystConor McNamara - Equity Research AnalystJack Meehan - Equity Research ...

SalMar ASA (rated BBB+ by Nordic Credit Rating) has today issued a new commercial paper of NOK 1 000,000,000. Issue date: 13 March 2025 Maturity date: 15 September 2025 Coupon: 5.04 % p.a. Manager: DNB Markets About SalMar SalMar is one of the world's largest and most efficient producers of salmon. The Group has farming operations in Central Norway, Northern Norway and Iceland, as well as substantial harvesting and secondary processing operations. In addition, the company is operating within offshore aquacu ...